MedPacto, Inc.

KOSDAQ 235980.KQ

MedPacto, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2023: -47.35%

MedPacto, Inc. Return on Capital Employed (ROCE) is -47.35% for the year ending December 31, 2023, a 35.49% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

MedPacto, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -73.40%, a -990.50% change year over year.
MedPacto, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -6.73%, a 86.07% change year over year.
MedPacto, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -48.32%, a -190.90% change year over year.
MedPacto, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -16.61%.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

KOSDAQ: 235980.KQ

MedPacto, Inc.

CEO	Mr. Seong-Jin Kim
IPO Date	Dec. 19, 2019
Location	South Korea
Headquarters	Borim Building
Employees	57
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea.

Key trends

Past 5 years